Menu Search
Equities

Novartis AG

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NOVNEE:SWX

Novartis AG

Actions
  • Price (CHF)120.34
  • Today's Change1.48 / 1.25%
  • Shares traded180.00k
  • 1 Year change+22.95%
  • Beta--
Data delayed at least 15 minutes, as of Feb 06 2026 15:40 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		NOVN:SWX since
announced		Transaction
value
Avidity Biosciences IncAnnounced26 Oct 202526 Oct 2025Announced15.26%9.99bn
Tourmaline Bio IncDeal completed09 Sep 202509 Sep 2025Deal completed17.24%1.37bn
Regulus Therapeutics IncDeal completed30 Apr 202530 Apr 2025Deal completed27.33%1.62bn
Anthos Therapeutics IncDeal completed11 Feb 202511 Feb 2025Deal completed23.75%3.08bn
Data delayed at least 15 minutes, as of Feb 06 2026 16:35 GMT.

Institutional shareholders

0.00%Per cent of shares held by top holders
HolderShares% Held
GQG Partners LLCas of 30 Jun 2025374.50k0.00%
Massachusetts Financial Services Co.as of 31 Dec 2025180.82k0.00%
LUKB Expert Fondsleitung AGas of 31 Jul 2025123.24k0.00%
Pyrford International Ltd.as of 30 Jun 202539.70k0.00%
Nomura Asset Management Co., Ltd.as of 30 Dec 202511.82k0.00%
Fnb Stockbroking & Portfolio Management Pty Ltd. (Invt Mgmt)as of 30 Sep 20256.00k0.00%
Columbia Threadneedle Management Ltd.as of 31 Mar 20251.02k0.00%
Melville Douglas Investment Management (Pty) Ltd.as of 30 Sep 2025415.000.00%
Morgan Stanley AIP GP LPas of 30 Jun 2024237.000.00%
Swiss Rock Asset Management AGas of 31 Dec 20240.000.00%
More ▼
Data from 31 Jul 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.